BSF Enterprise PLC (LSE:BSFA), a biotechnology company developing cell-based tissue engineering and biomaterial technologies, announced on 2 November 2026 that it is extending its technology platform into humanoid robotics and physical artificial intelligence (AI).
The expansion involves applying tissue-assembly technology developed by its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), to the production of seamless external coverings for robotic hands and articulated components.
The company has filed a UK priority patent application covering tissue-assembly methods that could be used to manufacture robotic hand coverings incorporating tactile sensor systems.
BSF intends to pursue commercial development through partnerships with robotics manufacturers, with the objective of securing externally funded development programmes.
3D Bio-Tissues Files Patent Application Covering Robotic Hand Technology
3DBT has submitted a priority patent application to the UK Intellectual Property Office titled “Tissue Assembly Method and/or Tissue Assembly”.
The application, numbered GB2622781.9, has a priority date of 28 September 2026.
The filing covers methods for producing seamless tissue structures, including potential applications involving humanoid robotic hands, articulated fingers and coverings positioned over tactile sensor arrays.
BSF said the technology builds on its existing tissue-engineering platform, which is already being used in commercial evaluation programmes involving biomaterials for the luxury fashion industry.
The application represents an extension of the company’s intellectual property development activities into a new potential market.
Technology Builds on Existing Luxury Biomaterials Programmes
The robotic coverings are based on the same three-dimensional tissue-assembly architecture being developed by BSF subsidiary Lab-Grown Leather Ltd.
The company said its monolithic manufacturing process enables tissue structures to be produced as continuous, stitchless components rather than assembled from separate sections.
Lab-Grown Leather is currently conducting contracted, partner-funded commercial evaluation programmes with two global luxury fashion houses.
These programmes involve the development of three-dimensional moulded biomaterial structures for potential use in luxury products.
BSF intends to apply the underlying manufacturing approach to robotic components, although commercial adoption within the robotics industry has not yet been established.
Proposed Robotic Coverings Designed for Articulated Hands and Sensors
BSF outlined several technical characteristics of its proposed robotic covering technology, which is intended to address mechanical and sensor integration requirements in humanoid robotics.
The tissue-assembly method is designed to produce single-piece coverings with variable thickness across different sections of a robotic hand.
According to the company, the proposed structure could incorporate thicker material over finger pads while allowing sections as thin as 0.3 millimetres around articulated joints.
This configuration is intended to provide wear resistance in areas subject to contact while maintaining flexibility around moving components.
The company also said the collagen-based material is designed to transfer contact forces to underlying tactile sensors, potentially allowing the coverings to operate alongside pressure and touch-detection systems.
Another feature involves manufacturing at temperatures below 40°C, which BSF said could allow tissue structures to be formed around components without the higher-temperature processing required for certain synthetic materials.
These technical characteristics form part of the proposed application of the company’s tissue-engineering platform. The announcement did not provide completed robotics durability testing results or confirm commercial deployment of the coverings.
US Patent Application Receives Notice of Allowance
BSF also highlighted developments involving its existing intellectual property portfolio.
The company’s proprietary macromolecular crowding (MMC) technology has received a Notice of Allowance from the United States Patent and Trademark Office covering 17 claims under US patent application 18/578,286.
The claims relate to methods supporting the production of skin, corneal tissue and extracellular matrix materials.
The MMC technology forms part of 3DBT’s upstream tissue-production platform, while the newer UK application addresses downstream tissue assembly and potential finished-component applications.
BSF is seeking to use these technologies across multiple commercial sectors, including luxury biomaterials and robotics.
Robotics Commercialisation to Focus on Partner-Funded Agreements
BSF plans to pursue a business-to-business commercialisation strategy for its proposed robotic skin technology.
The company intends to seek Joint Development Agreements (JDAs) with established robotics original equipment manufacturers and automation developers.
Under the proposed arrangements, commercial partners would fund application-specific development activities, including computer-aided design tooling, sensor integration and durability testing.
BSF said this approach is intended to limit the amount of central company funding required for the new robotics development programme.
The company also confirmed that 3DBT would retain full legal ownership of its foundational synthesis intellectual property, cell lines and proprietary media formulations, including CityMix® and CytoBoost™.
Subject to technical development and commercial agreements, BSF envisages supplying custom-moulded robotic hand coverings and related components to manufacturers.
No completed robotics Joint Development Agreements, customer orders or associated revenue commitments were disclosed in the announcement.
CEO Comments on Robotics Expansion
Dr. Che Connon, Chief Executive Officer of BSF Enterprise PLC, commented:
“Our core objective across BSF is taking breakthrough tissue-engineering intellectual property originated in our laboratories and driving it into high-margin, scalable commercial markets.
“This priority patent filing demonstrates the sheer versatility of 3D Bio-Tissues’ platform. The exact same monolithic, stitchless 3D tissue architecture that we are currently executing under funded commercial programmes with global luxury fashion houses via Lab-Grown Leather translates directly into solving the most demanding component challenge in modern humanoid robotics.
“By eliminating seams, preserving sensor sensitivity, and allowing direct moulding over complex articulating joints, this technology positions 3DBT as an indispensable hardware partner for the emerging physical AI revolution. Crucially, we will execute this vertical via partner-funded development agreements, securing long-term high-margin component supply while protecting our group cash runway.”
More About BSF Enterprise PLC
BSF Enterprise PLC is a biotechnology company focused on developing and commercialising cell-based tissue engineering and biomaterial technologies.
Its wholly owned subsidiary, 3D Bio-Tissues Limited, develops tissue-production and assembly technologies, including proprietary media formulations and three-dimensional tissue structures.
Through Lab-Grown Leather Ltd, the Group is conducting commercial evaluation programmes involving biomaterials for the luxury fashion sector.
The company is now exploring additional applications for its tissue-engineering technology in humanoid robotics, with commercial development expected to depend on future partnerships, technical validation and customer agreements.
Leave a Reply